search
Back to results

Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome (OBEMINALE2)

Primary Purpose

Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Stablor
placebo
Sponsored by
LNC THERAPEUTICS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Female or male
  • Age between 18 and 65 years (limits included),
  • BMI between 27 and 40 kg/m² (limits included),
  • With metabolic syndrome: Waist circumference > 94 cm for male (>90 cm for male of South-East Asian, Chinese and Japanese ethnic groups) and > 80 cm for female and at least two of the following criteria :

    • Triglycerides levels ≥ 1.5 g/L (1.71 mmol/L) or stable under treatment for at least 6 months,
    • HDL cholesterol levels <0.40 g/L (1.03 mmol/L) for male and <0.5 g/l (1.29 mmol/L) for female or stable under treatment for at least 6 months,
    • Fasting plasma glucose ≥1 g/L (5.6 mmol/L) and non-diabetic,
    • Blood pressure ≥130 mmHg (systolic) and/or 85 mmHg (diastolic) or stable under antihypertensive treatment for at least 6 months,
  • Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
  • Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,

Exclusion Criteria:

  • Suffering from a metabolic disorder such as diabetes uncontrolled thyroidal trouble or other metabolic disorder,
  • Suffering from a cardiac insufficiency, inflammatory disease, severe hepatic of renal insufficiency, or gastrointestinal disorders (Crohn's disease or Ulcerative Colitis) or others diseases found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease),
  • Having suffered of stroke or ictus within the last 6 months,
  • Suffering of depression,
  • Had a major surgical procedure within the last 6 months,
  • Had a bariatric surgery,
  • With a known or suspected food allergy or intolerance to lactose or soja, or hypersensitivity to any of the study products' ingredient,
  • Who does not like the investigational product flavors "vanilla-toffee", "chocolate" and "coffee",
  • Having a biological selection profile considered as abnormal by the investigator (BUN, Creatinine, calcium, Liver enzymes (GGT, AST, ALT), Blood Cell Count, , HIV, HCV, lipids (TG, HDL, LDL, total cholesterol),glycaemia, B HCG),
  • Pregnant (positive pregnancy test at selection visit) or lactating women or intending to become pregnant within 6 months ahead,
  • Women of child bearing potential without efficient contraception,
  • Under nutritional supplement or drugs acting on weight or satiety according to the investigator or stopped less than 6 months before the study,
  • With a current or planned in the next 6 months specific diet (hypocaloric, vegan, vegetarian…) or stopped less than 6 months before the study,
  • Treated with drugs acting on visceral fat mass &inflammation : corticosteroids, neuroleptics, alpha et beta blockers, anti-HIV tritherapy, anti-TNF alpha, antidepressant or anticoagulating agents,
  • Treated with antibiotics in the 3 months prior to selection,
  • With significant change in food habits or in physical activity in the 6 months before the V0 visit,
  • With significant changes in lipid abnormality of antihypertensive treatment within 3 months prior to selection,
  • With a personal history of bulimia or significant eating disorders according to the investigator,
  • Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
  • Consuming tobacco more than 10 mg of nicotine per day
  • Consuming drugs,
  • Patients who suffer from claustrophobia,
  • Patients who have contraindications to perform an MRI such as pacemakers, intracranial clips incompatible with MRI, heart valves, hearing aid,... and other types of implants incompatible with MRI,
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
  • Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
  • Presenting a psychological or linguistic incapability to sign the informed consent,
  • Impossible to contact in case of emergency.

Sites / Locations

  • CEN Experimental
  • Eurofins Optimed
  • Institut Pasteur de Lille
  • CIC Pitié Salpêtrière
  • Biofortis
  • Atlantia Food Clinical Trials

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Stablor

placebo

Arm Description

2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks

2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks

Outcomes

Primary Outcome Measures

Absolute change of visceral fat mass (in cubic millimeter) assessed by Magnetic Resonance Imaging

Secondary Outcome Measures

Change of visceral fat mass in percentage assessed by Magnetic Resonance Imaging
Changes of total abdominal fat mass in cubic millimeter assessed by Magnetic Resonance Imaging
Changes of subcutaneous fat mass in cubic millimeter assessed by Magnetic Resonance Imaging
Changes of total abdominal fat mass in percentage assessed by Magnetic Resonance Imaging
Changes of subcutaneous fat mass in percentage assessed by Magnetic Resonance Imaging
Changes of body fat mass measured by Dual-energy X-ray absorptiometry
Changes of body lean mass measured by Dual-energy X-ray absorptiometry
Changes of trunk fat assessed by Dual-energy X-ray absorptiometry
calculated trunk fat
Changes of anthropometrics measurements : weight
Weight
Changes of anthropometrics measurements : BMI
BMI
Changes of anthropometrics measurements: Waist circumference
Waist Circumference
Changes of anthropometrics measurements: Hip Circumference
Hip Circumference
Changes of anthropometrics measurements: Waist to Hip ratio
Waist to Hip ratio
Changes of anthropometrics measurements: Waist to Height ratio
Waist to Height ratio

Full Information

First Posted
September 10, 2018
Last Updated
December 16, 2020
Sponsor
LNC THERAPEUTICS
Collaborators
Biofortis Mérieux NutriSciences, StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame
search

1. Study Identification

Unique Protocol Identification Number
NCT03692806
Brief Title
Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
Acronym
OBEMINALE2
Official Title
A 3-month Randomized Double Blind Placebo-controlled Multicenter Study to Assess the Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
September 11, 2018 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
December 16, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LNC THERAPEUTICS
Collaborators
Biofortis Mérieux NutriSciences, StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.
Detailed Description
It is expected that the food product STABLOR will reduce visceral fat mass in subjects with metabolic syndrome and therefore will improve cardiometabolic risk factors. The aim of the current study is to assess the impact of a 12-week intake of STABLOR, compared to a placebo, on visceral fat in patients with metabolic syndrome. The primary objective of the study is to assess the efficacy of 12-week STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome. The Secondary outcomes include Anthropometric measurements and body composition, metabolic syndrome status, STABLOR® metabolism, Cardiovascular biomarkers, Systemic inflammation, Quality of life and Behavior.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Stablor
Arm Type
Experimental
Arm Description
2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Stablor
Intervention Description
Stablor sachet
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
placebo sachet
Primary Outcome Measure Information:
Title
Absolute change of visceral fat mass (in cubic millimeter) assessed by Magnetic Resonance Imaging
Time Frame
between week 0, week 9, week 12
Secondary Outcome Measure Information:
Title
Change of visceral fat mass in percentage assessed by Magnetic Resonance Imaging
Time Frame
between Week 0, Week 9 and Week 12
Title
Changes of total abdominal fat mass in cubic millimeter assessed by Magnetic Resonance Imaging
Time Frame
between Week 0, Week 9 and Week 12
Title
Changes of subcutaneous fat mass in cubic millimeter assessed by Magnetic Resonance Imaging
Time Frame
between Week 0, Week 9 and Week 12
Title
Changes of total abdominal fat mass in percentage assessed by Magnetic Resonance Imaging
Time Frame
between Week 0, Week 9 and Week 12
Title
Changes of subcutaneous fat mass in percentage assessed by Magnetic Resonance Imaging
Time Frame
between Week 0, Week 9 and Week 12
Title
Changes of body fat mass measured by Dual-energy X-ray absorptiometry
Time Frame
between Week 0 and Week 12
Title
Changes of body lean mass measured by Dual-energy X-ray absorptiometry
Time Frame
between Week 0 and Week 12
Title
Changes of trunk fat assessed by Dual-energy X-ray absorptiometry
Description
calculated trunk fat
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements : weight
Description
Weight
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements : BMI
Description
BMI
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements: Waist circumference
Description
Waist Circumference
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements: Hip Circumference
Description
Hip Circumference
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements: Waist to Hip ratio
Description
Waist to Hip ratio
Time Frame
between Week 0 and Week 12
Title
Changes of anthropometrics measurements: Waist to Height ratio
Description
Waist to Height ratio
Time Frame
between Week 0 and Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female or male Age between 18 and 65 years (limits included), BMI between 27 and 40 kg/m² (limits included), With metabolic syndrome: Waist circumference > 94 cm for male (>90 cm for male of South-East Asian, Chinese and Japanese ethnic groups) and > 80 cm for female and at least two of the following criteria : Triglycerides levels ≥ 1.5 g/L (1.71 mmol/L) or stable under treatment for at least 6 months, HDL cholesterol levels <0.40 g/L (1.03 mmol/L) for male and <0.5 g/l (1.29 mmol/L) for female or stable under treatment for at least 6 months, Fasting plasma glucose ≥1 g/L (5.6 mmol/L) and non-diabetic, Blood pressure ≥130 mmHg (systolic) and/or 85 mmHg (diastolic) or stable under antihypertensive treatment for at least 6 months, Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination, Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form, Exclusion Criteria: Suffering from a metabolic disorder such as diabetes uncontrolled thyroidal trouble or other metabolic disorder, Suffering from a cardiac insufficiency, inflammatory disease, severe hepatic of renal insufficiency, or gastrointestinal disorders (Crohn's disease or Ulcerative Colitis) or others diseases found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease), Having suffered of stroke or ictus within the last 6 months, Suffering of depression, Had a major surgical procedure within the last 6 months, Had a bariatric surgery, With a known or suspected food allergy or intolerance to lactose or soja, or hypersensitivity to any of the study products' ingredient, Who does not like the investigational product flavors "vanilla-toffee", "chocolate" and "coffee", Having a biological selection profile considered as abnormal by the investigator (BUN, Creatinine, calcium, Liver enzymes (GGT, AST, ALT), Blood Cell Count, , HIV, HCV, lipids (TG, HDL, LDL, total cholesterol),glycaemia, B HCG), Pregnant (positive pregnancy test at selection visit) or lactating women or intending to become pregnant within 6 months ahead, Women of child bearing potential without efficient contraception, Under nutritional supplement or drugs acting on weight or satiety according to the investigator or stopped less than 6 months before the study, With a current or planned in the next 6 months specific diet (hypocaloric, vegan, vegetarian…) or stopped less than 6 months before the study, Treated with drugs acting on visceral fat mass &inflammation : corticosteroids, neuroleptics, alpha et beta blockers, anti-HIV tritherapy, anti-TNF alpha, antidepressant or anticoagulating agents, Treated with antibiotics in the 3 months prior to selection, With significant change in food habits or in physical activity in the 6 months before the V0 visit, With significant changes in lipid abnormality of antihypertensive treatment within 3 months prior to selection, With a personal history of bulimia or significant eating disorders according to the investigator, Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study, Consuming tobacco more than 10 mg of nicotine per day Consuming drugs, Patients who suffer from claustrophobia, Patients who have contraindications to perform an MRI such as pacemakers, intracranial clips incompatible with MRI, heart valves, hearing aid,... and other types of implants incompatible with MRI, Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision, Presenting a psychological or linguistic incapability to sign the informed consent, Impossible to contact in case of emergency.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie Déciron, MD
Organizational Affiliation
BioFortis
Official's Role
Principal Investigator
Facility Information:
Facility Name
CEN Experimental
City
Dijon
ZIP/Postal Code
21000
Country
France
Facility Name
Eurofins Optimed
City
Gières
ZIP/Postal Code
38610
Country
France
Facility Name
Institut Pasteur de Lille
City
Lille
ZIP/Postal Code
59019
Country
France
Facility Name
CIC Pitié Salpêtrière
City
Paris
ZIP/Postal Code
75651
Country
France
Facility Name
Biofortis
City
Saint Herblain
ZIP/Postal Code
44800
Country
France
Facility Name
Atlantia Food Clinical Trials
City
Cork
Country
Ireland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome

We'll reach out to this number within 24 hrs